Mycosis Fungoides - 29 Studies Found
| Completed |
: Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides : Mycosis Fungoides : 2005-09-07 : Drug: mechlorethamine-MCH (nitrogen mustard) All affected areas (lesions) are to be treated once daily f |
| Terminated |
: Study of Low-Dose Total Skin Electron Beam Therapy in Mycosis Fungoides : Mycosis Fungoides : 2007-07-02 : Device: Low-dose total skin electron beam therapy (4 Gy) |
| Not yet recruiting |
: Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides : Mycosis Fungoides : 2016-10-18 :
|
| Withdrawn |
: Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides. : Mycosis Fungoides : 2005-09-13 : Drug: CPG 7909 |
| Completed |
: An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides : Mycosis Fungoides : 2007-09-24 : Drug: 0.04% Mechlorethamine gel Mechlorethamine 0.04% PG applied to affected skin areas (lesions) once d |
| Active, not recruiting |
: PUVA Maintenance Therapy in Mycosis Fungoides : Patch/Plaque Stage Mycosis Fungoides : 2012-05-09 : Drug: 8-methoxypsoralen 8-methoxypsoralen 10mg per 20 kg body weight 1 hour before UVA exposure |
| Recruiting |
: Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma : Mycosis Fungoides : 2014-11-07 : Drug: Valchlor Valchlor gel 0.016% Other Name: Mechl |
| Recruiting |
: Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome :
: 2005-09-07 : Drug: alemtuzumab |
| Terminated |
: Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome :
: 2005-08-08 : Drug: HuMax-CD4 (zanolimumab) Monoclonal Antibody, 12 weekly infusions. |
| Terminated |
: PUVA Versus PUVA + IFN Alpha 2a in Mycosis Fungoides : Cutaneous T-Cell Lymphoma (Mycosis Fungoides) : 2008-02-28 :
|